News | July 30, 2024
Pfizer Ltd. posts Q1 FY25 PAT at Rs. 150.71 Cr
Pfizer Ltd. has reported total income of Rs. 604.70 crores during the period ended June 30, 2024
Pfizer Ltd. has reported total income of Rs. 604.70 crores during the period ended June 30, 2024
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
This marks the first partnership between Pfizer and Cipla in India
The new facility is expected to generate 500-600 new jobs in the region
The state-of-the-art facility is expected to be commissioned over the next three years
This recognition demonstrate excellence in intellectual property (IP) value creation.
The company shall process the change of name application with BSE Ltd. in due course
Subscribe To Our Newsletter & Stay Updated
